# Heart Failure

> The clinical syndrome that develops when the heart cannot maintain adequate output, or can do so only at the expanse of elevated ventricular filling pressure.

## Types

1. **Left heart failure**
   - A reduction in left ventricular output and an increase in left atrial and pulmonary venous pressure
   - Example causes: `Acute MI`, `Mitral stenosis`
1. **Right heart failure**
   - A reduction in right ventricular output and an increase in right atrial and systemic venous pressure
   - Common causes: `Chronic lung disease`, `Pulmonary embolism`, `Pulmonary valvular stenosis`
1. **Biventricular heart failure**
   - Both sides of the heart are affected.
   - Example causes: `Dilated cardiomyopathy (DCM)`, `Coronary heart disease`

## Causes

> မညှစ်နိုင်၊ ထွက်ပေါက်ပိတ်၊ ဝင်ပေါက်ပိတ်၊ အဝင်များ၊ Diastolic, Arrhythmia

1. **Reduced Ventricular Contractility**
   - `Myocardial infarction` (_segmental dysfunction_)
   - `Myocarditis`, `Cardiomyopathy` (_global dysfunction_)
1. **Ventricular Outflow Obstruction (Pressure Overload)**
   - `Hypertension`, `Aortic stenosis` (_left heart failure_)
   - `Pulmonary hypertension`, `Pulmonary valve stenosis` (_right heart failure_)
1. **Ventricular Inflow Obstruction**
   - `Mitral stenosis`, `Tricuspid stenosis`
1. **Ventricular Volume Overload**
   - `Mitral regurgitation`, `Aortic regurgitation` (_left ventricular_)
   - `Ventricular septal defect`
   - `Atrial septal defect` (_right ventricular_)
   - `Increased metabolic demand` (_high output_)
1. **Diastolic Dysfunction**
   - `Constrictive pericarditis`
   - `Restrictive cardiomyopathy`
   - `Left ventricular hypertrophy and fibrosis`
   - `Cardiac tamponade`
1. **Arrhythmia**
   - `Atrial fibrillation`
   - `Tachycardia`
   - `Complete heart block`

## Precipitating Factors

> I FAIL Drug Therapy PATH

1. Myocardial **i**schaemia or infarction
1. Intravenous **f**luid overload
1. **A**rrhythmia
1. Intercurrent **i**llness
1. **L**ung (Pulmonary) embolism
1. **Drug** with negative inotropic (β-blocker) or fluid-retaining properties (NSAIDs, glucocorticoids)
1. Inappropriate reduction of **therapy**
1. Increase metabolic demand (**P**regnancy, **A**naemia, **Th**yrotoxicosis)

## Clinical Features

### Acute Left Heart Failure

- _Due to decreased cardiac output_:
  - Agitated, pale, cold and clammy extremities, rapid pulse, high blood pressure
  - Cardiogenic shock (BP may be normal or low)
- _Due to increased backward pressure_:
  - Dyspnoea (at rest, sudden onset) → Respiratory distress, Orthopnoea, Respiratory Failure
  - Crepitations at lung base, or throughout the lungs if severe
- _Due to increase end-diastolic pressure_:
  - Gallop rhythm (Triple rhythm) with a 3rd heart sound
- History of a clear precipitating factor (such as acute MI)
- Increase JVP if right heart failure
- **Apex is not displaced**

### Chronic Heart Failure

- _Due to decreased cardiac output_:
  - Fatigue, Poor effort tolerance
  - Low blood pressure, Cold peripheries
  - Oliguria, Nocturia, Uraemia (← Poor renal perfusion)
- _Due to increased backward pressure_:
  - Dyspnoea, Pulmonary oedema, Inspiratory crepitations over the lung base (← Left heart failure)
- _Due to right heart failure_:
  - High JVP with hepatic congestion → Ascites, Pleural effusion
  - Dependent peripheral oedema (lower legs, sacrum)
  - Sometimes: Marked weight loss (**cardiac cachexia**) ← Anorexia, Poor absorption due to congested GI tract

<details>
<summary>Differential Diagnosis of Peripheral Oedema</summary>

1. **Cardiac failure**:
   - Right or Biventricular heart failure
   - Pericardial constriction
   - Cardiomyopathy
1. **Hypoalbuminaemia**: Often widespread, can affect arms and face
   - Nephrotic syndrome
   - Liver disease
   - Protein-losing enteropathy
1. **Drugs**:
   - **Sodium retention**: `Fludrocortisone`, `NSAIDs`
   - **Increasing capillary permeability**: `Nifedipine`, `Amlodipine` (dihydropyridine calcium channel blockers)
1. **Chronic venous insufficiency**: Varicose veins
1. **Chronic lymphatic obstruction**
1. **Idiopathic**: Women > Men

</details>

### Acute-on-chronic Heart Failure

- Clinical features of Acute heart failure + Chronic heart failure
- Precipitated by URTI or inappropriate cessation of diuretics

## Complications

import { Tabs } from "nextra/components";

<Tabs items={["Simple", "Details"]}>

<Tabs.Tab>

1. Renal failure
1. Impaired liver function (_mild jaundice_)
1. Hypokalaemia
1. Hyperkalaemia
1. Hyponatraemia (_Poor prognostic sign_)
1. Thromboembolism (_DVT, systemic or pulmonary embolism, Stroke_)
1. Atrial and ventricular arrhythmia
1. Sudden death (_50%_)

</Tabs.Tab>

<Tabs.Tab>

1. Renal failure
   - Caused by: Poor renal perfusion, Low cardiac output
   - Worsen by: Diuretics, ACE inhibitors, ARB
1. Hypokalaemia
   - Caused by: Potassium-losing diuretics, Hyperaldosteronism from RAAS activation
1. Hyperkalaemia
   - Caused by: Potassium-sparing diuretics
1. Hyponatraemia
   - Features of severe heart failure (Poor prognostic sign)
   - Caused by: Diuretics, Inappropriate water retention
1. Impaired liver function
   - Caused by: Hepatic venous congestion, Poor arterial perfusion
   - Mild jaundice, Abnormal liver function tests
   - Reduced synthesis of clotting factors
1. Thromboembolism
   - DVT, Pulmonary embolism
   - Systemic embolism (Stroke)
1. Atrial and ventricular arrhythmia
   - Atrial fibrillation
   - Ventricular tachycardia
1. Sudden death (50%)
   - Mostly due to ventricular tachycardia

</Tabs.Tab>

</Tabs>

## Investigation

1. **Erect chest X-ray** (_in all cases_)
   - **A**lveolar edema (batwing apperance)
   - Pulmonary oedema ('Kerley **B**' lines)
   - **C**ardiomegaly
   - Abnormal **d**istension of upper lobe pulmonary veins
   - Pleural **e**ffusion
1. **Echocardiography** (_in all cases_)
   - Determine aetiology
   - Detect valvular heart disease
   - Decision of treatment plan (Long-term drug or cardiac device implantation)
1. **BNP, NT-proBNP**
   - Prognostic marker
   - Increase when ventricular filling pressures are high
   - Check NT-proBNP in patients on `ARNI (angiotensin receptor neprilysin inhibitors)`
1. **Serum urea, creatine & electrolytes**
   - Renal function to choose drug
1. **ECG**
   - No specific of heart failure
   - Identify ischemia, infarct, ventricular hypertrophy or arrhythmia
1. **Full blood count** & **Haemoglobin**
   - Anaemic heart failure
1. **Liver function tests**
   - Congestive liver
1. **Thyroid function tests**
   - Thyrotoxicosis or myxoedema
1. **Cardiac biopsy**
   - Cardiomyopathy

## Management

### General Management

> SAVED

1. `S`moking
   - Cessation of smoking
1. `A`lcohol
   - Reduction or cessation of alcohol consumption
1. `V`accination
   - Consideration of influenza and pneumococcal vaccination
1. `E`ducation
   - Explanation of nature of disease, treatment and self-help strategies
1. `E`xercise
   - Regular moderate exercise within limit
1. `D`iet
   - Good nutrition and weight reduction
   - Avoidance of salty foods

### Management of Acute Heart Failure

> Acute heart failure with pulmonary oedema is a medical emergency!!!

<Tabs items={["Simple", "Details"]}>
<Tabs.Tab>

1. Sit the patient upright, with continuous monitoring of vital signs
1. Give high-flow `oxygen`
1. Ensure continuous positive airway pressure (CPAP)
1. Administer nitrates: `IV glyceryl trinitrate`, `Buccal glyceryl trinitrate`
1. Administer a loop diuretics: `Furosemide`
1. If ineffective, add inotropic agents: `Dobutamine`
1. IV `opiates` for distressed patients
1. Continue for long-term management

</Tabs.Tab>
<Tabs.Tab>

1. Sit the patient upright, with continuous monitoring of cardiac rhythm, BP and pulse oximetry (_Reduce preload_)
1. Give high-flow oxygen (_Correct hypoxia_)
1. Ensure continuous positive airway pressure (CPAP) of 5-10 mmHg by tight-fitting mask (_Reduce preload and pulmonary capillary hydraulic gradient_)
1. Administer nitrates: (_Reduces preload and afterload_)
   - `IV glyceryl trinitrate (10-200 μg/min)`
   - `Buccal glyceryl trinitrate (2-5 mg)`
1. Administer a loop diuretics: (_Combats fluid overload, Reduces preload, afterload_)
   - `Furosemide (50-100 mg IV)`
1. If ineffective, add inotropic agents:
   - `Dobutamine (2.5 - 10 μg/kg/min)`
1. IV opiates for distressed patients
1. Continue for long-term management

</Tabs.Tab>

</Tabs>

### Management of Chronic Heart Failure

#### Pharmacological Management

<Tabs items={['Simple', 'Details']}>

<Tabs.Tab>

> Digoxin and Diuretics have only symptomatic benefit. The rest have both symptomatic and mortality benefit.

1. Angiotensin-converting enzyme inhibitors (ACE inhibitors)
   - `Enalapril`, `Lisinopril`, `Captopril`
1. Angiotensin receptor blockers (ARB)
   - `Losartan`, `Valsartan`, `Candesartan`
1. Angiotension receptor neprilysin inhibitors (ARNI)
   - `Sacubitril + Valsartan`
1. `Amiodarone`
1. Beta-adrenoceptor antagonists (β-blockers)
   - `Bisoprolol`, `Carvedilol`, `Metoprolol`
1. Diuretics
   - Loop diuretics: `Furosemide`
   - Thiazide diuretics: `Bendroflumethiazide`
   - Mineralocorticoid receptor antagonists: `Spironolactone`, `Eplerenone`
   - SGLT2 inhibitors: `Canagliflozin`, `Empagliflozin`
1. `Digoxin`
1. Vasodilators
   - `Nitrates`, `Hydralazine`
1. `Ivabradine`

</Tabs.Tab>

<Tabs.Tab>

##### 1. Diuretics

- Promote sodium and water excretion → ↓ blood volume and ↓ preload → Improve pulmonary and systemic venous congestion
- ↓ afterload → Increase cardiac effciency

1. Oral loop diuretics (`furosemide`)
   - If oedema persists, IV infusion of loop diuretic (`furosemide` 5-10 mg/hr) ± Thiazide diuretics (`bendroflumethiazide` 5 mg daily)
   - Side effects: ~~Hypotension~~, ~~Hypokalaemia~~, ~~Hyponatraemia~~, ~~Renal failure~~
1. Potassium-sparing diuretics (`spironolactone`, `eplerenone`)
   - Side effects: ~~Hyperkalaemia~~
1. SGLT-2 inhibitors (`canagliflozin`, `empagliflozin`)
   - Side effects: ~~Risk of Genito-urinary tract infection~~ and ~~DKA~~

##### 2. ACE inhibitors

- `Enalapril`, `Captopril`, `Lisinopril`
- Interrupt RAAS by preventing the conversion of angiotensin I to angiotensin II → ↓ vasoconstriction, ↓ salt and water retention
- Also prevent activation of RAAS caused by diuretic therapy
- Improve effort tolerance and reduce mortality
- Side effects: ~~Hypotension~~, ~~Renal impairment~~, ~~Hyperkalaemia~~
- Monitor renal function and serum potassium for 1-2 weeks

##### 3. ARB

- `Losartan`, `Valsartan`, `Candesartan`
- Block the action of angiotensin II on the heart, peripheral vasculature and kidneys
- Alternative for patients who can't tolerate ACE inhibitors
- Combined therapy with ACE inhibitors for resistant or recurrent heart failure
- Same side effects as ACE inhibitors

##### 4. Neprilysin Inhibitors

- `Sacubitril` (the only drug)
- Break down the endogenous diuretics ANP and BNP
- `Sacubitril 24 mg + Valsartan (ARB) 26 mg` daily
- Reduce mortality

##### 5. Vasodilators

- Venodilators (`nitrates`) reduces preload
- Atrial dilators (`hydralazine`) reduces afterload
- Useful when ACE inhibitors or ARBs are contraindicated

##### 6. β-blockers

- `Bisoprolol`, `Carvedilol`, `Metoprolol`
- Reduce risk of arrhythmia and sudden death
- Reduce mortality
- If given in standard dose, may precipitate acute-on-chronic heart failure
- Give small incremental doses
- `Bisoprolol` (starting 1.25 mg daily and increased gradually over 12 weeks to maintenance dose 10 mg daily)

##### 7. `Ivabradine`

- Reduce heart rate (best for patients who cannot take `β-blockers`)
- `Ivabradine` 2.5-5 mg twice daily
- Reduce mortality
- Ineffective in patients with atrial fibrillation

##### 8. `Digoxin`

- Provide rate control in patients with heart failure and atrial fibrillation
- Maintenance dose 0.0625-0.25 mg daily
- No effect on long-term survival

##### 9. `Amiodarone`

- Anti-arrhythmic drug
- Effective only in treatment of symptomatic arrhythmia
- Should not use as preventive agent

</Tabs.Tab>

</Tabs>

<details>

<summary>
  Four pillars used in HFrEF (heart failure with reduced ejection fraction) ejection fraction < 40% 
</summary>

> BAMS

1. `β`-blockers
   - `Bisoprolol`, `Carvedilol`, `Metoprolol`
1. `A`ngiotension receptor neprilysin inhibitors (ARNI)
   - `Sacubitril + Valsartan`
1. `M`RA (Mineralocorticoid Receptor Antagonists)
   - `Spironolactone`, `Eplerenone`
1. `S`GLT2i (Sodium-Glucose Co-Transporter 2 Inhibitors)
   - `Canagliflozin`, `Empagliflozin`, `Dapagliflozin`

</details>

#### Non-Pharmacological Management

1. Implantable cardiac defibrillators
1. Cardiac resynchronisation therapy (CRT) devices
1. Coronary revascularisation
1. Cardiac transplantation
1. Ventricular assist devices
